Literature DB >> 11945113

Cyclo-oxygenase-2 inhibitors and the kidney: a case for caution.

Gary Noroian1, David Clive.   

Abstract

Cyclo-oxygenase (COX) is one of the key enzymes in the biosynthesis of prostaglandins. Two isoforms of this enzyme COX-1 and COX-2 are known to exist. Among other functions, prostaglandins play an important role in the protection of the gastric mucosa and maintenance of renal function in pathophysiological conditions which would otherwise threaten it. Conventional nonsteroidal anti-inflammatory drugs (NSAIDs) block prostaglandin synthesis, resulting in gastric mucosal injury and renal dysfunction in susceptible individuals. The recent introduction of selective COX-2 inhibitors, celecoxib and rofecoxib, appear to induce less gastrointestinal morbidity. Although conclusive data are still lacking, there is evidence to suggest that COX-2 antagonists may be capable of causing some of the same renal syndromes seen in association with the older, less selective NSAIDs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11945113     DOI: 10.2165/00002018-200225030-00003

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  40 in total

1.  Natriuretic response to increased pressure is preserved with COX-2 inhibitors.

Authors:  J M Gross; J E Dwyer; F G Knox
Journal:  Hypertension       Date:  1999-11       Impact factor: 10.190

2.  Cyclooxygenase-2 mediates increased renal renin content induced by low-sodium diet.

Authors:  P Harding; D H Sigmon; M E Alfie; P L Huang; M C Fishman; W H Beierwaltes; O A Carretero
Journal:  Hypertension       Date:  1997-01       Impact factor: 10.190

Review 3.  Adverse effects of nonsteroidal anti-inflammatory drugs on the kidney.

Authors:  M T Stillman; J Napier; J L Blackshear
Journal:  Med Clin North Am       Date:  1984-03       Impact factor: 5.456

4.  Cyclooxygenase-1 and cyclooxygenase-2 expression in rat kidney and adrenal gland after stimulation with systemic lipopolysaccharide: in situ hybridization and immunocytochemical studies.

Authors:  Y Ichitani; K Holmberg; A B Maunsbach; J Z Haeggström; B Samuelsson; D De Witt; T Hökfelt
Journal:  Cell Tissue Res       Date:  2001-02       Impact factor: 5.249

5.  Are selective COX-2 inhibitors nephrotoxic?

Authors:  M A Perazella; J Eras
Journal:  Am J Kidney Dis       Date:  2000-05       Impact factor: 8.860

6.  Chronic cyclooxygenase-2 inhibition blunts low sodium-stimulated renin without changing renal haemodynamics.

Authors:  P Harding; O A Carretero; W H Beierwaltes
Journal:  J Hypertens       Date:  2000-08       Impact factor: 4.844

7.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors:  F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal:  JAMA       Date:  2000-09-13       Impact factor: 56.272

8.  Postnatal development and progression of renal dysplasia in cyclooxygenase-2 null mice.

Authors:  V F Norwood; S G Morham; O Smithies
Journal:  Kidney Int       Date:  2000-12       Impact factor: 10.612

Review 9.  Nonsteroidal antiinflammatory drugs and renal function.

Authors:  M J Dunn
Journal:  Annu Rev Med       Date:  1984       Impact factor: 13.739

10.  An open study to assess the safety and tolerability of meloxicam 15 mg in subjects with rheumatic disease and mild renal impairment.

Authors:  P J Bevis; H A Bird; G Lapham
Journal:  Br J Rheumatol       Date:  1996-04
View more
  6 in total

Review 1.  Valdecoxib.

Authors:  Douglas Ormrod; Keri Wellington; Antona J Wagstaff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  COX-2 inhibitors: a CLASS act or Just VIGORously promoted.

Authors:  Samir Malhotra; N Shafiq; P Pandhi
Journal:  MedGenMed       Date:  2004-03-23

Review 3.  Renal failure associated with the use of celecoxib and rofecoxib.

Authors:  Syed R Ahmad; Cindy Kortepeter; Allen Brinker; Min Chen; Julie Beitz
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

4.  Effects of NSAIDs on the incidence of hospitalisations for renal dysfunction in users of ACE inhibitors.

Authors:  Marcel L Bouvy; Eibert R Heerdink; Arno W Hoes; Hubert G M Leufkens
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

5.  Attitude and Awareness of Dentists Practicing in Southern India Toward Non-steroidal Anti-inflammatory Drugs.

Authors:  Maria Monisha; Tatu Joy Elengickal; Shashi Kiran Mohan Ram; Malu L Madhu; Maneesha Raghuveeran; Rahul Raveendran Pillai
Journal:  J Pharm Bioallied Sci       Date:  2019-05

Review 6.  Nonsteroidal Anti-Inflammatory Drugs and the Kidney.

Authors:  Walter H Hörl
Journal:  Pharmaceuticals (Basel)       Date:  2010-07-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.